2月26日，港股三大指数呈现高开低走行情，尾盘加速下跌。 截止收盘，恒生科技指数大跌2.87%，创去年7月以来新低，较去年10月高点回调超23%，恒生指数、国企指数分别下跌1.44%及2.44%。 | 名称 | 最新价 | 涨跌额 | 涨跌幅 ^ | | --- | --- | --- | --- | | 恒生科技指数 | 5109.33 | -151.17 | -2.87% | | 800700 | | | | | 国企指数 | 8814.29 | -220.46 | -2.44% | | 800100 | | | | | 恒生指数 | 26381.02 | -384.70 | -1.44% | | 800000 | | | | 具体盘面上，大型科技股、大金融股(银行、保险、券商)、中字头等权重集体下跌大市承压十分明显，汽车经销商股大跌，生物医药股、建材水泥股、濠赌 股、AI应用概念股、煤炭股、石油股、内房股、光伏股、黄金等有色金属股纷纷下跌。电力设备股逆市上扬，影视股部分反弹，存储概念股再度活跃。 | 行业热力图 × | 领域板块 | | | | | | | | | | --- | --- | --- | ...

医药生物板块重挫，百济神州跌逾9%，药明合联跌超8%，药明生物跌逾7%。 科网股全线走低，小鹏汽车跌逾5%，华虹半导体、理想汽车、快手、哔哩哔哩、百度集团跌逾4%，阿 里巴巴、腾讯音乐、携程集团、中芯国际跌超3%，腾讯控股、京东集团、美团跌超2%。 | 名称 | 涨跌幅 ▲ | 现价 | 涨跌 | | --- | --- | --- | --- | | 小鹏汽车-W | -5.06% | 67.500c | -3.600 | | 本町未合体 | -4.82% | 97.850c -4.950 | | | 昨週昨回-W | -4.63% | 218.200c -10.600 | | | 理想汽车-W | -4.45% | 68.650c -3.200 | | | 目度集团-SW | -4.27% | 123.400c -5.500 | | | 快手-W | -4.14% | 63.600c | -2.750 | | 地平线机器人-W | -4.11% | 8.160c -0.350 | | | 阿里健康 | -3.97% | 5.560c -0.230 | | | 零跑汽车 | -3.90% | 41.380c ...

2月26日下午，港股医疗保健板块内的290只个股，六成以上出现下跌，其中有61只个股跌幅超过4%， 其中德琪医药（06996.HK）、百济神州（06160.HK）、药明合联（02268.HK）三只个股跌幅领衔，分 别大跌10.44%、9.16%、8.69%。 伴随着股价大跌，百济神州2月26日在港股市场的市值跌破3000亿港元，最后报2995亿港元。 | 自杀神州(06160.HK) | | | | | --- | --- | --- | --- | | 已收盘 02-26 16:08:14 | | | | | 港交所规定,港股基础行情需手动下拉刷新 | | | | | 194.400 HKD | | gr | 窝 通 BMP | | -19.600 -9.16% 生物技术 -5.96% > | | | | | 今 开 最 高 213.400 | 213.400 | | 成交量 601.23万股 | | 昨 收 最 低 194.000 | 214.000 | | 成交额 12.06亿 | | 换手率 市盈 TM (2 561.39 | 0.42% | | 总市值 ▼ 2995.08亿 | | 量 比 而容动 ...

港股创新药板块持续走弱，百济神州跌超8%，药明生物跌超7%，泰格医药、康龙化成、诺诚健华跟 跌。 ...

2月26日午后，港股医药股加速走低，创新药产业链跌幅靠前，港股通创新药ETF（520880） 、港股通 医疗ETF华宝（159137）双双跌逾2%，场内溢价同步走高，显示"抄底"资金有所行动。 个股方面，权重龙头百济神州跌逾6%居首，据悉，该公司将于今日披露2025年财报。作为创新药领域 龙头企业，百济神州为港股通创新药ETF（520880） 、港股通医疗ETF华宝（159137）持仓股，权重占 比分别为11.27%、2.13%。 开源证券指出，中国创新药正经历从"规模积累"走向"价值释放"的国际化跨越，并持续迎来从"管线预 期"转向"业绩兑现"的商业化收获期。创新药板块已回调两个季度，长期看，较多优质标的估值性价比 明显，当前位置建议加大关注。* 低位埋伏港股医药机遇，借道ETF效率更高，高弹性，T+0！ 投创新药，认准港股通创新药ETF（520880）及其场外联接基金（025221），100%布局创新药研发类 公司，前十大权重股占比超七成，龙头属性突出。 投医疗，选港股通医疗ETF华宝（159137），锚定医疗创新，囊括脑机接口、AI医疗、互联网药店等热 点概念，同时覆盖创新药全产业链龙头。 数据来源：中 ...

2月26日，百济神州跌5.27%，截至发稿，报264.50元/股，成交10.74亿元，换手率3.47%，总市值 4075.09亿元。 资料显示，百济神州有限公司位于北京市昌平区中关村生命科学园科学园路30号，成立日期2010年10月 28日，上市日期2021年12月15日，公司主营业务涉及研究、开发、生产以及商业化创新型药物。主营业 务收入构成为：药品销售收入99.10%，合作安排收入0.90%。 从基金十大重仓股角度 数据显示，摩根士丹利基金旗下1只基金重仓百济神州。大摩健康产业混合A（002708）四季度持有股 数23.18万股，与上期相比持股数量不变，占基金净值比例为4.12%，位居第七大重仓股。根据测算，今 日浮亏损失约341.23万元。 大摩健康产业混合A（002708）成立日期2016年6月30日，最新规模14.23亿。今年以来亏损0.47%，同 类排名8462/8887；近一年收益0.89%，同类排名7892/8134；成立以来收益69.9%。 大摩健康产业混合A（002708）基金经理为王大鹏。 截至发稿，王大鹏累计任职时间11年39天，现任基金资产总规模19.97亿元，任职期间最佳基金回报 ...

2月26日，百济神州跌5.27%，截至发稿，报264.50元/股，成交10.74亿元，换手率3.47%，总市值 4075.09亿元。 资料显示，百济神州有限公司位于北京市昌平区中关村生命科学园科学园路30号，成立日期2010年10月 28日，上市日期2021年12月15日，公司主营业务涉及研究、开发、生产以及商业化创新型药物。主营业 务收入构成为：药品销售收入99.10%，合作安排收入0.90%。 从基金十大重仓股角度 数据显示，中信保诚基金旗下1只基金重仓百济神州。中信保诚中证800医药指数(LOF)A（165519）四 季度持有股数1.19万股，占基金净值比例为1.99%，位居第十大重仓股。根据测算，今日浮亏损失约 17.55万元。 中信保诚中证800医药指数(LOF)A（165519）成立日期2021年1月1日，最新规模1.47亿。今年以来收益 1.77%，同类排名4581/5572；近一年收益16.18%，同类排名3257/4311；成立以来收益89.35%。 中信保诚中证800医药指数(LOF)A（165519）基金经理为黄稚。 截至发稿，黄稚累计任职时间7年219天，现任基金资产总规模44.18亿 ...

A股算力芯片概念午后拉升，消息面上，OpenAI讨论扩大云服务协议以纳入亚马逊Tranium芯片。此 外，英伟达2026财年第四季度财报，营收、净利润及下一季度指引全面超越市场预期，提振了市场信 心。 东莞证券指出，从海内外已披露业绩或业绩预告的企业情况看，半导体行业整体景气度上行但细分领域 分化，其中AI对算力芯片、存储芯片、晶圆代工等细分领域的需求端拉动作用明显，而非AI相关细分 则呈温和复苏态势，部分细分领域如消费类电子，因AI需求挤占存储等资源导致成本上升，景气整体 承压。展望后续，建议继续关注AI带来的高景气细分领域的投资机会，如算力、存力、先进封装、先 进制程晶圆代工、半导体设备与材料等。 截至2026年2月26日 13:45，上证科创板100指数(000698)强势上涨，成分股安路科技上涨13.11%，华曙 高科上涨13.05%，华丰科技上涨11.26%，云天励飞，信科移动等个股跟涨。科创100ETF鹏华(588220) 上涨1.22%，最新价报1.58元。 科创100ETF鹏华(588220)，场外联接(A：019861；C：019862；I：022845)。 MACD金叉信号形成，这些股涨势 ...

Group 1 - The pharmaceutical sector is experiencing significant growth, with BD transaction volumes reaching new highs and domestic innovative drugs gaining international recognition, making it a focal point for investors [1][3] - However, there is a growing fatigue regarding the expectations for innovative drugs going abroad, leading to a shift from a "highlight moment" to a "volatile adjustment" in the market [2][3] - This transition is viewed as a necessary step towards a long-term market trend, with signs of recovery in the pharmaceutical sector as it approaches a new cycle starting in 2026 [3][11] Group 2 - The current investment rationale in the pharmaceutical sector is supported by three main forces: demand, supply, and policy, which are converging to fuel a new round of growth [5][36] - Demand for healthcare is increasing due to an aging population and rising health awareness, transforming medical consumption from optional to essential [6][37] - The supply side shows that China's innovative drugs are becoming globally competitive, with the number of innovative drug pipelines accounting for nearly 30% of the global total and BD overseas licensing transactions reaching $135.7 billion in 2025, a 161% increase year-on-year [7][38] Group 3 - Policy changes are shifting from cost control to empowerment, with new measures introduced to support the entire chain of innovative drug development, access, usage, and payment [10][41] - The Hong Kong stock market is becoming a primary platform for Chinese innovative drug companies due to its flexible listing regulations and foreign investment environment, which has attracted over 70 competitive innovative drug and CXO companies [12][43] - The establishment of the Hong Kong Medical Device Regulatory Center (CMPR) and other supportive mechanisms is expected to enhance the internationalization and business development capabilities of companies listed in Hong Kong [13][44] Group 4 - The Hang Seng Biotechnology Index has outperformed other indices with a 82.75% increase, highlighting its strong market position [16][46] - The index is composed of the top 30 biotechnology companies, focusing on high-growth sectors such as innovative drugs (79% weight) and CXO services (11% weight), ensuring coverage of the core segments of the pharmaceutical industry [17][49] - The index's unique feature includes being the only pharmaceutical-themed index in Hong Kong equipped with index futures, providing risk management tools and enhancing liquidity for investors [23][54] Group 5 - The Hang Seng Biotechnology Index is currently at a historically low valuation, with a PE ratio of 30.01, significantly lower than the NASDAQ Biotechnology Index and the CSI Biotechnology Index, indicating a valuation advantage [26][55] - The index's components are primarily leading innovative drug and CXO companies with solid R&D capabilities, suggesting potential for steady profit release as pipelines mature and orders are fulfilled [28][57] - The current market conditions may present a favorable opportunity for long-term investors to allocate resources into high-quality pharmaceutical assets through the Hang Seng Biotechnology ETF [29][58]

Core Viewpoint - The Hong Kong innovative drug sector is experiencing a pullback, with the Hong Kong Stock Connect innovative drug ETF (159570) declining over 1.5%, despite a net inflow of over 14 million yuan [1][4]. Fund Performance - The innovative drug ETF has seen a cumulative capital inflow of over 360 million yuan in the past 10 days, with a total scale exceeding 25 billion yuan, leading in its category [1]. - As of February 13, 2026, the ETF has increased by over 70% since the second half of 2023, outperforming the Hong Kong pharmaceutical index [9][10]. Market Dynamics - Major stocks within the ETF, such as CSPC Pharmaceutical Group and BeiGene, have experienced declines of over 3%, while companies like Kangfang Biotech have shown slight gains [2][4]. - The innovative drug sector is expected to see a recovery driven by upcoming performance disclosures and clinical data releases in the near term [3]. Investment Opportunities - According to Guojin Securities, the innovative drug sector is poised for recovery due to a significant number of clinical data catalysts and the successful overseas clinical progress of pipelines [3]. - The number of License-out transactions for new drugs in China is projected to reach 158 by 2025, with a total transaction value of 135.7 billion USD, marking a decade-high in both quantity and value [3]. Clinical Data and Commercialization - Key clinical data releases are anticipated in 2025, with significant results expected from drugs like AK112 and IBI363, which could positively impact market valuations [7]. - The commercialization of innovative drugs is supported by recent policy measures aimed at enhancing the development of innovative pharmaceuticals [6].